Personalized therapeutic approaches for improved glycemic outcomes in type 2 diabetes
- PMID: 40487623
- PMCID: PMC12142185
- DOI: 10.4239/wjd.v16.i5.104841
Personalized therapeutic approaches for improved glycemic outcomes in type 2 diabetes
Abstract
Managing type 2 diabetes mellitus remains a significant challenge, particularly for individuals with persistently poor glycemic control. Although inadequate glycemic regulation is a well-established public health concern and a major contributor to diabetes-related complications, evidence on the effectiveness of intensive and supportive interventions across diverse patient subgroups is scarce. This editorial examines findings from a prospective study evaluating the influence of glycemic history on treatment outcomes in poorly controlled diabetes. The study highlights that personalized care models outperform generalized approaches by addressing the unique trajectories of glycemic deterioration. Newly diagnosed patients demonstrated the most favorable response to intervention, while those with consistently elevated glycated hemoglobin (≥ 10%) faced the greatest challenges in achieving glycemic control. These findings underscore the limitations of a one-size-fits-all strategy, reinforcing the need for patient-centered care that integrates individualized monitoring and timely intervention. Diabetes management requires prioritizing personalized treatment strategies that mitigate therapeutic inertia and ensure equitable, effective care for all patients.
Keywords: Diabetes control; Glycated hemoglobin improvement; Glycemic trajectories; Metabolic challenges; Personalized treatment; Therapeutic inertia.
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
References
-
- Khan F, Hussain T, Chaudhry TZ, Payal F, Shehryar A, Rehman A, Ramadhan A, Hayat MT, Dabas MM, Khan M. Comparing the Efficacy and Long-Term Outcomes of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Metformin, and Insulin in the Management of Type 2 Diabetes Mellitus. Cureus. 2024;16:e74400. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources